AtriCure, Inc. ATRC
AtriCure's 7.5x revenue valuation assumes stand-alone Convergent succeeds, but electrophysiologists won't refer, and PFA plus real-time mapping will obsolete surgical ablation.
Thesis
AtriCure is a $1.9bn medical device company whose revenue depends on surgical cardiac ablation for atrial fibrillation, with roughly 80% of sales tied to open-heart concomitant procedures. Kerrisdale argues the core market is already ~80% penetrated — not the 20-25% management repeats — leaving little organic growth, and that AtriCure has been disingenuous about TAM for a decade. The bull case rests on Convergent, a hybrid minimally invasive procedure, but electrophysiologists won't refer patients for something they can already perform alone via outpatient catheter ablation. Worse, pulsed field ablation from Farapulse, Medtronic, Abbott and Affera, plus Acutus's real-time AcQMap mapping, are making catheter ablation dramatically safer and faster, threatening to obsolete both Convergent and AtriCure's concomitant surgical business. At 7.5x revenue with structural unprofitability, the multiple should compress sharply.
SCQA
AtriCure is a $1.9bn medical device maker whose surgical ablation equipment treats atrial fibrillation, with 80% of revenue tied to concomitant procedures performed during open-heart surgery.
The concomitant market is ~80% penetrated, not 20-25% as management claims, and new catheter technologies — PFA and real-time mapping — are making minimally invasive surgical ablation obsolete just as AtriCure bets growth on Convergent.
Kerrisdale is short ATRC, betting Convergent fails commercially because EPs refuse referrals, while PFA and Acutus's AcQMap cannibalize both the stand-alone and concomitant surgical ablation markets.
At 7.5x forward revenue, ATRC trades at a decade-high multiple despite structural unprofitability; as growth stalls and the disruption thesis materializes, the multiple should compress sharply toward peers.
The three reasons
- 1
Core surgical ablation market is ~80% penetrated, not the 20-25% AtriCure claims
- 2
Convergent will fail because electrophysiologists can perform the same ablation alone by catheter
- 3
Pulsed field ablation and real-time mapping will obsolete surgical ablation entirely
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- RESTORE-SR II (AtriCure's prior failed minimally invasive trial)
- DEEP AF trial (AtriCure's prior failed hybrid procedure)
- STAR AF II catheter ablation trial
Notable slides (5)
Notes
Short report (not a deck) in prose research-note format with embedded anatomical diagrams and a capitalization table. Core argument blends technological-obsolescence thesis (PFA, AcQMap) with TAM-misrepresentation accusation ('AtriCure has been disingenuous about the addressable market'). No individual author credited. No explicit price target, just EV/revenue framing. Campaign phase coded as initial_thesis — first Kerrisdale short on ATRC. thesis_types uses fraud_exposure for the TAM-misleading accusations and multiple_rerating for the overvaluation case; not a classic accounting-fraud report.